Registration and export: different legal questions

Start with the origin position

Identify the product, manufacturing site and legal entity involved. Establish what activities are authorised at origin and what the product’s registration status is. The answer needs to concern the actual presentation and transaction, rather than only the active substance or the company’s business licence.

An initial regulatory brief should state whether the proposed goods are a finished medicine, active substance, biological material, device or diagnostic. Different product categories can require different evidence and permissions, even when they appear in the same commercial portfolio.

What a product certificate can communicate

The WHO model Certificate of a Pharmaceutical Product provides a structured way to describe the product and applicant’s position in the exporting country. It distinguishes licence status, whether the product is actually marketed, and information concerning manufacture and inspection.

Read the completed document and its attachments as a whole. A certificate must not be reduced to a headline that implies every product, presentation or destination has been approved. The importing authority determines how the document is used within its own process.

Identify the destination pathway

The destination needs a lawful basis for the particular import, distribution and intended use. Depending on the jurisdiction and circumstances, this may involve normal product registration or a specifically applicable permit or exception. The existence and conditions of any exception require verification; they should never be assumed from a buyer’s willingness to receive the goods.

A free-zone company may have permissions relevant to particular commercial or logistics activities. That status alone does not establish permission to place every medicine on the local market, supply patients or distribute into another country.

Formats help organise evidence

The ASEAN Common Technical Dossier organises administrative/product information, quality, nonclinical and clinical material. The HSA guidance collection makes ACTD documents available alongside Singapore-specific submission guidance.

These are useful professional resources, but harmonised formatting does not remove national decisions or product-specific requirements. Reusing a dossier structure is different from assuming that one authorisation transfers automatically to another country.

Define who does what

Before a proposed transaction proceeds, the responsible parties should establish who holds the product and import permissions, who acts as importer, who stores and distributes the goods, and who handles required safety and quality communications. The physical route and any intermediate destination must also be understood.

Record the destination, product identity, intended channel and document requirements together. Where the commercial and regulatory descriptions disagree, resolve the inconsistency before treating the project as ready for supply. Price and delivery terms do not answer the authorisation question.

A useful initial enquiry

• Product identity, strength, form and pack presentation.
• Origin, destination and any proposed transit or re-export point.
• Buyer’s role and the intended end-use channel.
• Proposed authorisation or permit route.
• Documents requested and the competent authority involved.
• Product-specific storage and transport requirements.

This guide is an orientation for professional discussion. A live transaction requires current advice on the applicable jurisdictions and its exact facts. Luang Pharma is at the facility-development stage and does not currently offer supply from the Boten project.

Map the transaction before asking whether export is “allowed”

A cross-border pharmaceutical transaction normally involves at least four distinct questions: the legal status of the product at origin; the authority of the manufacturer or exporter; the import and product requirements at destination; and the licences or responsibilities of the importer, wholesaler or other receiving party. A lawful answer can differ by product, country and intended use.

Export documentation can support customs or regulatory review, but it does not automatically create marketing authorisation in the destination. Likewise, domestic registration in the country of manufacture does not by itself establish that another country permits import, distribution or sale.

Match each document to the decision it supports

A Certificate of Pharmaceutical Product, manufacturing authorisation, GMP certificate, free-sale document, certificate of analysis, invoice and transport document answer different questions. Before requesting “all certificates”, identify the decision the receiving authority or counterparty must make and the exact product and site to which the evidence must relate.

Current destination rules and competent-authority instructions take priority over a generic checklist. Professional counterparties should confirm the proposed supply chain, importer role, product status and required dossier before committing to a transaction.